Pulmonary Fibrosis

Yet Khor discusses why a 20% CT emphysema threshold, not spirometry alone, best identifies CPFE and predicts outcomes in fibrotic ILD.

A Chest study of 1576 patients finds a 20% emphysema threshold best predicts survival and lung function decline in fibrotic ILD.

A 3-cohort study finds CC16 levels flag airway remodeling and fibrosis-like lung damage up to 3 years after severe COVID-19.

Polygenic risk scores show promise for idiopathic pulmonary fibrosis (IPF), though clinical implementation challenges remain, said David Zhang, MD.

Large biobank study suggests a polygenic risk score may improve prediction of idiopathic pulmonary fibrosis diagnosis and outcomes.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

Pooled TETON trial data showed inhaled treprostinil preserved lung function in IPF, supporting an FDA submission planned for 2026.

CHMP issued a positive opinion for nerandomilast in IPF and PPF, bringing the therapy closer to European Union approval.

Invited commentaries on the CORAL trial praise nalbuphine's potential in IPF cough while raising questions about safety and durability.

Yet Khor, MD, PhD, discusses ILD care disparities, telehealth, trial awareness, and shared care strategies.

Patients with IPF hospitalized for CDI had higher mortality, longer stays, and greater costs.

TETON-1 data show inhaled treprostinil improves FVC and reduces worsening in IPF, supporting a potential new treatment and combo strategy.

Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis.

Explore frequently asked questions on IPF therapies, including approved drugs, emerging treatments, and approaches to slow fibrosis.

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.

A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations.

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

A study shows that PF impacts sexual activity physically and emotionally, emphasizing the need for holistic patient care and quality-of-life assessments.

Oral nalbuphine significantly reduced cough frequency and severity in idiopathic pulmonary fibrosis (IPF), with patients seeing greater benefit at higher doses.

Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis biomarkers, supporting disease-modifying potential in IPF.

Mass spectrometry technology identified proteomic biomarkers of IPF, but more work will be needed to fully translate these findings to the clinic.

Traditional Chinese medicine relies on nonlinear, unstructured data, but a new report suggests its practitioners can still benefit from machine learning, including in the treatment of idiopathic pulmonary fibrosis.

A look back at the breakthroughs in pulmonary fibrosis research, including FDA-approved treatments and innovative diagnostic techniques.